nodes	percent_of_prediction	percent_of_DWPC	metapath
Levobupivacaine—CYP3A4—Thiotepa—urinary bladder cancer	0.101	0.386	CbGbCtD
Levobupivacaine—CYP1A2—Fluorouracil—urinary bladder cancer	0.0626	0.239	CbGbCtD
Levobupivacaine—CYP1A2—Etoposide—urinary bladder cancer	0.0522	0.2	CbGbCtD
Levobupivacaine—CYP3A4—Etoposide—urinary bladder cancer	0.0274	0.105	CbGbCtD
Levobupivacaine—CYP3A4—Doxorubicin—urinary bladder cancer	0.0187	0.0713	CbGbCtD
Levobupivacaine—CYP3A4—Codeine and Morphine Metabolism—UGT2B7—urinary bladder cancer	0.00314	0.0504	CbGpPWpGaD
Levobupivacaine—CYP1A2—Arylamine metabolism—NAT2—urinary bladder cancer	0.00307	0.0493	CbGpPWpGaD
Levobupivacaine—SCN4A—L1CAM interactions—CNTN2—urinary bladder cancer	0.00247	0.0396	CbGpPWpGaD
Levobupivacaine—SCN10A—L1CAM interactions—CNTN2—urinary bladder cancer	0.00238	0.0381	CbGpPWpGaD
Levobupivacaine—Lidocaine—EGFR—urinary bladder cancer	0.00217	1	CrCbGaD
Levobupivacaine—CYP1A2—Estrogen metabolism—UGT2B7—urinary bladder cancer	0.00213	0.0342	CbGpPWpGaD
Levobupivacaine—CYP1A2—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.00188	0.0302	CbGpPWpGaD
Levobupivacaine—CYP3A4—Estrogen metabolism—UGT2B7—urinary bladder cancer	0.00164	0.0264	CbGpPWpGaD
Levobupivacaine—CYP1A2—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.00153	0.0245	CbGpPWpGaD
Levobupivacaine—CYP3A4—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.00145	0.0233	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aflatoxin B1 metabolism—GSTM1—urinary bladder cancer	0.00134	0.0215	CbGpPWpGaD
Levobupivacaine—CYP3A4—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.00118	0.0189	CbGpPWpGaD
Levobupivacaine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.00115	0.0185	CbGpPWpGaD
Levobupivacaine—CYP3A4—Aflatoxin B1 metabolism—GSTM1—urinary bladder cancer	0.00104	0.0166	CbGpPWpGaD
Levobupivacaine—SCN4A—Axon guidance—CNTN2—urinary bladder cancer	0.000932	0.015	CbGpPWpGaD
Levobupivacaine—SCN10A—Axon guidance—CNTN2—urinary bladder cancer	0.000899	0.0144	CbGpPWpGaD
Levobupivacaine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.00089	0.0143	CbGpPWpGaD
Levobupivacaine—CYP1A2—Arachidonic acid metabolism—CYP4B1—urinary bladder cancer	0.000847	0.0136	CbGpPWpGaD
Levobupivacaine—CYP1A2—Estrogen metabolism—NQO1—urinary bladder cancer	0.000822	0.0132	CbGpPWpGaD
Levobupivacaine—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.000732	0.0117	CbGpPWpGaD
Levobupivacaine—CYP1A2—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.000722	0.0116	CbGpPWpGaD
Levobupivacaine—CYP1A2—Phase II conjugation—GSTZ1—urinary bladder cancer	0.00069	0.0111	CbGpPWpGaD
Levobupivacaine—SCN4A—Developmental Biology—CNTN2—urinary bladder cancer	0.000665	0.0107	CbGpPWpGaD
Levobupivacaine—CYP1A2—Phase II conjugation—GSTO2—urinary bladder cancer	0.000654	0.0105	CbGpPWpGaD
Levobupivacaine—CYP1A2—Phase II conjugation—NAT1—urinary bladder cancer	0.000654	0.0105	CbGpPWpGaD
Levobupivacaine—CYP1A2—Estrogen Receptor Pathway—ESR1—urinary bladder cancer	0.000642	0.0103	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—CNTN2—urinary bladder cancer	0.000641	0.0103	CbGpPWpGaD
Levobupivacaine—CYP3A4—Estrogen metabolism—NQO1—urinary bladder cancer	0.000634	0.0102	CbGpPWpGaD
Levobupivacaine—CYP1A2—Estrogen metabolism—GSTM1—urinary bladder cancer	0.00063	0.0101	CbGpPWpGaD
Levobupivacaine—CYP1A2—Phase II conjugation—UGT2B7—urinary bladder cancer	0.000598	0.0096	CbGpPWpGaD
Levobupivacaine—CYP1A2—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000593	0.00952	CbGpPWpGaD
Levobupivacaine—Pruritus—Thiotepa—urinary bladder cancer	0.000589	0.000874	CcSEcCtD
Levobupivacaine—Pain—Fluorouracil—urinary bladder cancer	0.000589	0.000874	CcSEcCtD
Levobupivacaine—Paraesthesia—Cisplatin—urinary bladder cancer	0.000586	0.00087	CcSEcCtD
Levobupivacaine—Tachycardia—Etoposide—urinary bladder cancer	0.000584	0.000866	CcSEcCtD
Levobupivacaine—Dyspnoea—Cisplatin—urinary bladder cancer	0.000582	0.000864	CcSEcCtD
Levobupivacaine—Skin disorder—Etoposide—urinary bladder cancer	0.000581	0.000862	CcSEcCtD
Levobupivacaine—Hyperhidrosis—Etoposide—urinary bladder cancer	0.000578	0.000858	CcSEcCtD
Levobupivacaine—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000577	0.000857	CcSEcCtD
Levobupivacaine—Orthostatic hypotension—Doxorubicin—urinary bladder cancer	0.000576	0.000855	CcSEcCtD
Levobupivacaine—Diarrhoea—Thiotepa—urinary bladder cancer	0.00057	0.000845	CcSEcCtD
Levobupivacaine—Aspartate aminotransferase increased—Doxorubicin—urinary bladder cancer	0.000568	0.000843	CcSEcCtD
Levobupivacaine—Decreased appetite—Cisplatin—urinary bladder cancer	0.000568	0.000842	CcSEcCtD
Levobupivacaine—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000568	0.000842	CcSEcCtD
Levobupivacaine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.000565	0.00906	CbGpPWpGaD
Levobupivacaine—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000564	0.000836	CcSEcCtD
Levobupivacaine—Infestation NOS—Methotrexate—urinary bladder cancer	0.000562	0.000834	CcSEcCtD
Levobupivacaine—Infestation—Methotrexate—urinary bladder cancer	0.000562	0.000834	CcSEcCtD
Levobupivacaine—Drowsiness—Methotrexate—urinary bladder cancer	0.000562	0.000834	CcSEcCtD
Levobupivacaine—Hypotension—Etoposide—urinary bladder cancer	0.000559	0.000829	CcSEcCtD
Levobupivacaine—Pain—Cisplatin—urinary bladder cancer	0.000558	0.000828	CcSEcCtD
Levobupivacaine—CYP3A4—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.000557	0.00894	CbGpPWpGaD
Levobupivacaine—Muscular weakness—Doxorubicin—urinary bladder cancer	0.000557	0.000826	CcSEcCtD
Levobupivacaine—Alanine aminotransferase increased—Doxorubicin—urinary bladder cancer	0.000557	0.000826	CcSEcCtD
Levobupivacaine—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000554	0.000822	CcSEcCtD
Levobupivacaine—Dizziness—Thiotepa—urinary bladder cancer	0.000551	0.000817	CcSEcCtD
Levobupivacaine—Abdominal distension—Doxorubicin—urinary bladder cancer	0.000549	0.000815	CcSEcCtD
Levobupivacaine—Urticaria—Fluorouracil—urinary bladder cancer	0.000547	0.000812	CcSEcCtD
Levobupivacaine—Dysphagia—Doxorubicin—urinary bladder cancer	0.000546	0.00081	CcSEcCtD
Levobupivacaine—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000544	0.000808	CcSEcCtD
Levobupivacaine—Sweating—Methotrexate—urinary bladder cancer	0.000539	0.000799	CcSEcCtD
Levobupivacaine—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000538	0.000798	CcSEcCtD
Levobupivacaine—Paraesthesia—Etoposide—urinary bladder cancer	0.000537	0.000797	CcSEcCtD
Levobupivacaine—Haematuria—Methotrexate—urinary bladder cancer	0.000536	0.000795	CcSEcCtD
Levobupivacaine—Dyspnoea—Etoposide—urinary bladder cancer	0.000533	0.000791	CcSEcCtD
Levobupivacaine—Somnolence—Etoposide—urinary bladder cancer	0.000532	0.000789	CcSEcCtD
Levobupivacaine—Vomiting—Thiotepa—urinary bladder cancer	0.000529	0.000786	CcSEcCtD
Levobupivacaine—Infestation—Epirubicin—urinary bladder cancer	0.000526	0.00078	CcSEcCtD
Levobupivacaine—Drowsiness—Epirubicin—urinary bladder cancer	0.000526	0.00078	CcSEcCtD
Levobupivacaine—Infestation NOS—Epirubicin—urinary bladder cancer	0.000526	0.00078	CcSEcCtD
Levobupivacaine—Headache—Thiotepa—urinary bladder cancer	0.000522	0.000774	CcSEcCtD
Levobupivacaine—Decreased appetite—Etoposide—urinary bladder cancer	0.00052	0.000772	CcSEcCtD
Levobupivacaine—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000516	0.000766	CcSEcCtD
Levobupivacaine—Body temperature increased—Cisplatin—urinary bladder cancer	0.000516	0.000766	CcSEcCtD
Levobupivacaine—Neuropathy peripheral—Epirubicin—urinary bladder cancer	0.000515	0.000765	CcSEcCtD
Levobupivacaine—Pain—Etoposide—urinary bladder cancer	0.000511	0.000759	CcSEcCtD
Levobupivacaine—Constipation—Etoposide—urinary bladder cancer	0.000511	0.000759	CcSEcCtD
Levobupivacaine—Urinary tract infection—Epirubicin—urinary bladder cancer	0.000511	0.000758	CcSEcCtD
Levobupivacaine—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000507	0.000753	CcSEcCtD
Levobupivacaine—Sweating—Epirubicin—urinary bladder cancer	0.000504	0.000748	CcSEcCtD
Levobupivacaine—Asthenia—Gemcitabine—urinary bladder cancer	0.000503	0.000746	CcSEcCtD
Levobupivacaine—Haematuria—Epirubicin—urinary bladder cancer	0.000501	0.000744	CcSEcCtD
Levobupivacaine—Pruritus—Gemcitabine—urinary bladder cancer	0.000496	0.000735	CcSEcCtD
Levobupivacaine—Nausea—Thiotepa—urinary bladder cancer	0.000495	0.000734	CcSEcCtD
Levobupivacaine—Feeling abnormal—Etoposide—urinary bladder cancer	0.000493	0.000731	CcSEcCtD
Levobupivacaine—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000489	0.000726	CcSEcCtD
Levobupivacaine—Pruritus—Fluorouracil—urinary bladder cancer	0.000487	0.000723	CcSEcCtD
Levobupivacaine—Infestation—Doxorubicin—urinary bladder cancer	0.000486	0.000722	CcSEcCtD
Levobupivacaine—Drowsiness—Doxorubicin—urinary bladder cancer	0.000486	0.000722	CcSEcCtD
Levobupivacaine—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000486	0.000722	CcSEcCtD
Levobupivacaine—CYP3A4—Estrogen metabolism—GSTM1—urinary bladder cancer	0.000486	0.0078	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor—HPGDS—urinary bladder cancer	0.000481	0.00772	CbGpPWpGaD
Levobupivacaine—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000481	0.000714	CcSEcCtD
Levobupivacaine—Bradycardia—Epirubicin—urinary bladder cancer	0.00048	0.000713	CcSEcCtD
Levobupivacaine—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000479	0.000711	CcSEcCtD
Levobupivacaine—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000477	0.000708	CcSEcCtD
Levobupivacaine—Urticaria—Etoposide—urinary bladder cancer	0.000475	0.000705	CcSEcCtD
Levobupivacaine—Body temperature increased—Etoposide—urinary bladder cancer	0.000473	0.000702	CcSEcCtD
Levobupivacaine—Abdominal pain—Etoposide—urinary bladder cancer	0.000473	0.000702	CcSEcCtD
Levobupivacaine—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000473	0.000702	CcSEcCtD
Levobupivacaine—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000471	0.000699	CcSEcCtD
Levobupivacaine—Tinnitus—Methotrexate—urinary bladder cancer	0.00047	0.000698	CcSEcCtD
Levobupivacaine—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.00047	0.000697	CcSEcCtD
Levobupivacaine—Asthenia—Cisplatin—urinary bladder cancer	0.000468	0.000695	CcSEcCtD
Levobupivacaine—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000468	0.000694	CcSEcCtD
Levobupivacaine—Sweating—Doxorubicin—urinary bladder cancer	0.000466	0.000692	CcSEcCtD
Levobupivacaine—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000465	0.00069	CcSEcCtD
Levobupivacaine—Haematuria—Doxorubicin—urinary bladder cancer	0.000464	0.000688	CcSEcCtD
Levobupivacaine—CYP3A4—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000458	0.00734	CbGpPWpGaD
Levobupivacaine—CYP3A4—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.000456	0.00731	CbGpPWpGaD
Levobupivacaine—Dizziness—Fluorouracil—urinary bladder cancer	0.000455	0.000676	CcSEcCtD
Levobupivacaine—Chills—Methotrexate—urinary bladder cancer	0.000452	0.000671	CcSEcCtD
Levobupivacaine—CYP1A2—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	0.00045	0.00722	CbGpPWpGaD
Levobupivacaine—Diarrhoea—Cisplatin—urinary bladder cancer	0.000447	0.000663	CcSEcCtD
Levobupivacaine—Vomiting—Gemcitabine—urinary bladder cancer	0.000445	0.000661	CcSEcCtD
Levobupivacaine—Bradycardia—Doxorubicin—urinary bladder cancer	0.000445	0.00066	CcSEcCtD
Levobupivacaine—Mental disorder—Methotrexate—urinary bladder cancer	0.000442	0.000656	CcSEcCtD
Levobupivacaine—Hypersensitivity—Etoposide—urinary bladder cancer	0.000441	0.000654	CcSEcCtD
Levobupivacaine—Tinnitus—Epirubicin—urinary bladder cancer	0.00044	0.000653	CcSEcCtD
Levobupivacaine—Malnutrition—Methotrexate—urinary bladder cancer	0.000439	0.000651	CcSEcCtD
Levobupivacaine—Erythema—Methotrexate—urinary bladder cancer	0.000439	0.000651	CcSEcCtD
Levobupivacaine—Headache—Gemcitabine—urinary bladder cancer	0.000439	0.000651	CcSEcCtD
Levobupivacaine—Flushing—Epirubicin—urinary bladder cancer	0.000438	0.00065	CcSEcCtD
Levobupivacaine—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000438	0.00065	CcSEcCtD
Levobupivacaine—Vomiting—Fluorouracil—urinary bladder cancer	0.000438	0.00065	CcSEcCtD
Levobupivacaine—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000434	0.000645	CcSEcCtD
Levobupivacaine—Headache—Fluorouracil—urinary bladder cancer	0.000431	0.00064	CcSEcCtD
Levobupivacaine—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.00043	0.000638	CcSEcCtD
Levobupivacaine—Asthenia—Etoposide—urinary bladder cancer	0.000429	0.000637	CcSEcCtD
Levobupivacaine—Back pain—Methotrexate—urinary bladder cancer	0.000425	0.00063	CcSEcCtD
Levobupivacaine—Chills—Epirubicin—urinary bladder cancer	0.000423	0.000628	CcSEcCtD
Levobupivacaine—Pruritus—Etoposide—urinary bladder cancer	0.000423	0.000628	CcSEcCtD
Levobupivacaine—Arrhythmia—Epirubicin—urinary bladder cancer	0.000422	0.000626	CcSEcCtD
Levobupivacaine—SCN4A—L1CAM interactions—SRC—urinary bladder cancer	0.000421	0.00675	CbGpPWpGaD
Levobupivacaine—Nausea—Gemcitabine—urinary bladder cancer	0.000416	0.000617	CcSEcCtD
Levobupivacaine—Vomiting—Cisplatin—urinary bladder cancer	0.000415	0.000616	CcSEcCtD
Levobupivacaine—Vision blurred—Methotrexate—urinary bladder cancer	0.000414	0.000614	CcSEcCtD
Levobupivacaine—Mental disorder—Epirubicin—urinary bladder cancer	0.000413	0.000614	CcSEcCtD
Levobupivacaine—Erythema—Epirubicin—urinary bladder cancer	0.000411	0.00061	CcSEcCtD
Levobupivacaine—Malnutrition—Epirubicin—urinary bladder cancer	0.000411	0.00061	CcSEcCtD
Levobupivacaine—Diarrhoea—Etoposide—urinary bladder cancer	0.000409	0.000607	CcSEcCtD
Levobupivacaine—Nausea—Fluorouracil—urinary bladder cancer	0.000409	0.000607	CcSEcCtD
Levobupivacaine—Tinnitus—Doxorubicin—urinary bladder cancer	0.000407	0.000604	CcSEcCtD
Levobupivacaine—SCN10A—L1CAM interactions—SRC—urinary bladder cancer	0.000406	0.00651	CbGpPWpGaD
Levobupivacaine—Anaemia—Methotrexate—urinary bladder cancer	0.000406	0.000602	CcSEcCtD
Levobupivacaine—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000405	0.000601	CcSEcCtD
Levobupivacaine—Flushing—Doxorubicin—urinary bladder cancer	0.000405	0.000601	CcSEcCtD
Levobupivacaine—Flatulence—Epirubicin—urinary bladder cancer	0.000405	0.000601	CcSEcCtD
Levobupivacaine—CYP1A2—Biological oxidations—GSTZ1—urinary bladder cancer	0.000404	0.00647	CbGpPWpGaD
Levobupivacaine—Tension—Epirubicin—urinary bladder cancer	0.000403	0.000598	CcSEcCtD
Levobupivacaine—Nervousness—Epirubicin—urinary bladder cancer	0.000399	0.000592	CcSEcCtD
Levobupivacaine—CYP1A2—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000398	0.00639	CbGpPWpGaD
Levobupivacaine—Back pain—Epirubicin—urinary bladder cancer	0.000397	0.00059	CcSEcCtD
Levobupivacaine—Dizziness—Etoposide—urinary bladder cancer	0.000396	0.000587	CcSEcCtD
Levobupivacaine—Muscle spasms—Epirubicin—urinary bladder cancer	0.000395	0.000586	CcSEcCtD
Levobupivacaine—Chills—Doxorubicin—urinary bladder cancer	0.000392	0.000581	CcSEcCtD
Levobupivacaine—Arrhythmia—Doxorubicin—urinary bladder cancer	0.00039	0.000579	CcSEcCtD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor—NQO1—urinary bladder cancer	0.000388	0.00622	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—NQO1—urinary bladder cancer	0.000388	0.00622	CbGpPWpGaD
Levobupivacaine—Nausea—Cisplatin—urinary bladder cancer	0.000388	0.000575	CcSEcCtD
Levobupivacaine—Vision blurred—Epirubicin—urinary bladder cancer	0.000387	0.000575	CcSEcCtD
Levobupivacaine—Cough—Methotrexate—urinary bladder cancer	0.000383	0.000568	CcSEcCtD
Levobupivacaine—CYP1A2—Biological oxidations—GSTO2—urinary bladder cancer	0.000383	0.00614	CbGpPWpGaD
Levobupivacaine—CYP1A2—Biological oxidations—NAT1—urinary bladder cancer	0.000383	0.00614	CbGpPWpGaD
Levobupivacaine—Mental disorder—Doxorubicin—urinary bladder cancer	0.000383	0.000568	CcSEcCtD
Levobupivacaine—Convulsion—Methotrexate—urinary bladder cancer	0.00038	0.000564	CcSEcCtD
Levobupivacaine—Vomiting—Etoposide—urinary bladder cancer	0.00038	0.000564	CcSEcCtD
Levobupivacaine—Erythema—Doxorubicin—urinary bladder cancer	0.00038	0.000564	CcSEcCtD
Levobupivacaine—Malnutrition—Doxorubicin—urinary bladder cancer	0.00038	0.000564	CcSEcCtD
Levobupivacaine—Anaemia—Epirubicin—urinary bladder cancer	0.00038	0.000563	CcSEcCtD
Levobupivacaine—Agitation—Epirubicin—urinary bladder cancer	0.000378	0.00056	CcSEcCtD
Levobupivacaine—CYP1A2—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000377	0.00605	CbGpPWpGaD
Levobupivacaine—Headache—Etoposide—urinary bladder cancer	0.000375	0.000556	CcSEcCtD
Levobupivacaine—Flatulence—Doxorubicin—urinary bladder cancer	0.000375	0.000556	CcSEcCtD
Levobupivacaine—Arthralgia—Methotrexate—urinary bladder cancer	0.000374	0.000555	CcSEcCtD
Levobupivacaine—Tension—Doxorubicin—urinary bladder cancer	0.000373	0.000554	CcSEcCtD
Levobupivacaine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000371	0.000551	CcSEcCtD
Levobupivacaine—Nervousness—Doxorubicin—urinary bladder cancer	0.000369	0.000548	CcSEcCtD
Levobupivacaine—SCN4A—L1CAM interactions—EGFR—urinary bladder cancer	0.000369	0.00592	CbGpPWpGaD
Levobupivacaine—Syncope—Epirubicin—urinary bladder cancer	0.000368	0.000547	CcSEcCtD
Levobupivacaine—Back pain—Doxorubicin—urinary bladder cancer	0.000368	0.000546	CcSEcCtD
Levobupivacaine—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000365	0.000542	CcSEcCtD
Levobupivacaine—Palpitations—Epirubicin—urinary bladder cancer	0.000363	0.000539	CcSEcCtD
Levobupivacaine—Confusional state—Methotrexate—urinary bladder cancer	0.000361	0.000536	CcSEcCtD
Levobupivacaine—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000361	0.000536	CcSEcCtD
Levobupivacaine—Cough—Epirubicin—urinary bladder cancer	0.000358	0.000532	CcSEcCtD
Levobupivacaine—CYP1A2—Phase II conjugation—NAT2—urinary bladder cancer	0.000358	0.00575	CbGpPWpGaD
Levobupivacaine—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000358	0.000532	CcSEcCtD
Levobupivacaine—Vision blurred—Doxorubicin—urinary bladder cancer	0.000358	0.000532	CcSEcCtD
Levobupivacaine—Convulsion—Epirubicin—urinary bladder cancer	0.000356	0.000528	CcSEcCtD
Levobupivacaine—Infection—Methotrexate—urinary bladder cancer	0.000356	0.000528	CcSEcCtD
Levobupivacaine—SCN10A—L1CAM interactions—EGFR—urinary bladder cancer	0.000356	0.00571	CbGpPWpGaD
Levobupivacaine—Nausea—Etoposide—urinary bladder cancer	0.000355	0.000527	CcSEcCtD
Levobupivacaine—Hypertension—Epirubicin—urinary bladder cancer	0.000355	0.000526	CcSEcCtD
Levobupivacaine—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000351	0.000521	CcSEcCtD
Levobupivacaine—Anaemia—Doxorubicin—urinary bladder cancer	0.000351	0.000521	CcSEcCtD
Levobupivacaine—CYP1A2—Biological oxidations—UGT2B7—urinary bladder cancer	0.00035	0.00561	CbGpPWpGaD
Levobupivacaine—Arthralgia—Epirubicin—urinary bladder cancer	0.00035	0.000519	CcSEcCtD
Levobupivacaine—Agitation—Doxorubicin—urinary bladder cancer	0.000349	0.000518	CcSEcCtD
Levobupivacaine—Anxiety—Epirubicin—urinary bladder cancer	0.000349	0.000517	CcSEcCtD
Levobupivacaine—Skin disorder—Methotrexate—urinary bladder cancer	0.000348	0.000516	CcSEcCtD
Levobupivacaine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000347	0.000515	CcSEcCtD
Levobupivacaine—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000346	0.000514	CcSEcCtD
Levobupivacaine—CYP1A2—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000345	0.00554	CbGpPWpGaD
Levobupivacaine—Syncope—Doxorubicin—urinary bladder cancer	0.000341	0.000506	CcSEcCtD
Levobupivacaine—Confusional state—Epirubicin—urinary bladder cancer	0.000338	0.000502	CcSEcCtD
Levobupivacaine—Palpitations—Doxorubicin—urinary bladder cancer	0.000336	0.000498	CcSEcCtD
Levobupivacaine—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000335	0.000498	CcSEcCtD
Levobupivacaine—Oedema—Epirubicin—urinary bladder cancer	0.000335	0.000498	CcSEcCtD
Levobupivacaine—Hypotension—Methotrexate—urinary bladder cancer	0.000335	0.000497	CcSEcCtD
Levobupivacaine—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000334	0.000496	CcSEcCtD
Levobupivacaine—Infection—Epirubicin—urinary bladder cancer	0.000333	0.000494	CcSEcCtD
Levobupivacaine—Cough—Doxorubicin—urinary bladder cancer	0.000332	0.000492	CcSEcCtD
Levobupivacaine—Shock—Epirubicin—urinary bladder cancer	0.00033	0.000489	CcSEcCtD
Levobupivacaine—Convulsion—Doxorubicin—urinary bladder cancer	0.000329	0.000489	CcSEcCtD
Levobupivacaine—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000329	0.000488	CcSEcCtD
Levobupivacaine—Hypertension—Doxorubicin—urinary bladder cancer	0.000328	0.000487	CcSEcCtD
Levobupivacaine—Tachycardia—Epirubicin—urinary bladder cancer	0.000327	0.000486	CcSEcCtD
Levobupivacaine—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000326	0.000484	CcSEcCtD
Levobupivacaine—Skin disorder—Epirubicin—urinary bladder cancer	0.000326	0.000483	CcSEcCtD
Levobupivacaine—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000324	0.000481	CcSEcCtD
Levobupivacaine—Insomnia—Methotrexate—urinary bladder cancer	0.000324	0.000481	CcSEcCtD
Levobupivacaine—Arthralgia—Doxorubicin—urinary bladder cancer	0.000324	0.00048	CcSEcCtD
Levobupivacaine—Anxiety—Doxorubicin—urinary bladder cancer	0.000322	0.000479	CcSEcCtD
Levobupivacaine—Paraesthesia—Methotrexate—urinary bladder cancer	0.000322	0.000477	CcSEcCtD
Levobupivacaine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000321	0.000477	CcSEcCtD
Levobupivacaine—Dyspnoea—Methotrexate—urinary bladder cancer	0.000319	0.000474	CcSEcCtD
Levobupivacaine—Somnolence—Methotrexate—urinary bladder cancer	0.000319	0.000473	CcSEcCtD
Levobupivacaine—Dyspepsia—Methotrexate—urinary bladder cancer	0.000315	0.000468	CcSEcCtD
Levobupivacaine—CYP1A2—Biological oxidations—CYP4B1—urinary bladder cancer	0.000315	0.00505	CbGpPWpGaD
Levobupivacaine—Hypotension—Epirubicin—urinary bladder cancer	0.000313	0.000465	CcSEcCtD
Levobupivacaine—Confusional state—Doxorubicin—urinary bladder cancer	0.000313	0.000464	CcSEcCtD
Levobupivacaine—CYP3A4—Biological oxidations—GSTZ1—urinary bladder cancer	0.000312	0.005	CbGpPWpGaD
Levobupivacaine—Decreased appetite—Methotrexate—urinary bladder cancer	0.000311	0.000462	CcSEcCtD
Levobupivacaine—CYP1A2—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000311	0.00499	CbGpPWpGaD
Levobupivacaine—Oedema—Doxorubicin—urinary bladder cancer	0.00031	0.00046	CcSEcCtD
Levobupivacaine—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.00031	0.00046	CcSEcCtD
Levobupivacaine—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000309	0.000459	CcSEcCtD
Levobupivacaine—Infection—Doxorubicin—urinary bladder cancer	0.000308	0.000457	CcSEcCtD
Levobupivacaine—CYP3A4—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000307	0.00493	CbGpPWpGaD
Levobupivacaine—Pain—Methotrexate—urinary bladder cancer	0.000306	0.000455	CcSEcCtD
Levobupivacaine—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000305	0.000453	CcSEcCtD
Levobupivacaine—Shock—Doxorubicin—urinary bladder cancer	0.000305	0.000453	CcSEcCtD
Levobupivacaine—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000304	0.000451	CcSEcCtD
Levobupivacaine—Insomnia—Epirubicin—urinary bladder cancer	0.000303	0.00045	CcSEcCtD
Levobupivacaine—Tachycardia—Doxorubicin—urinary bladder cancer	0.000303	0.000449	CcSEcCtD
Levobupivacaine—Skin disorder—Doxorubicin—urinary bladder cancer	0.000301	0.000447	CcSEcCtD
Levobupivacaine—Paraesthesia—Epirubicin—urinary bladder cancer	0.000301	0.000447	CcSEcCtD
Levobupivacaine—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.0003	0.000445	CcSEcCtD
Levobupivacaine—Dyspnoea—Epirubicin—urinary bladder cancer	0.000299	0.000444	CcSEcCtD
Levobupivacaine—Somnolence—Epirubicin—urinary bladder cancer	0.000298	0.000442	CcSEcCtD
Levobupivacaine—CYP3A4—Biological oxidations—NAT1—urinary bladder cancer	0.000295	0.00474	CbGpPWpGaD
Levobupivacaine—CYP3A4—Biological oxidations—GSTO2—urinary bladder cancer	0.000295	0.00474	CbGpPWpGaD
Levobupivacaine—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000295	0.000438	CcSEcCtD
Levobupivacaine—Dyspepsia—Epirubicin—urinary bladder cancer	0.000295	0.000438	CcSEcCtD
Levobupivacaine—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000293	0.000435	CcSEcCtD
Levobupivacaine—Decreased appetite—Epirubicin—urinary bladder cancer	0.000291	0.000432	CcSEcCtD
Levobupivacaine—CYP3A4—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000291	0.00467	CbGpPWpGaD
Levobupivacaine—Hypotension—Doxorubicin—urinary bladder cancer	0.00029	0.00043	CcSEcCtD
Levobupivacaine—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000289	0.00043	CcSEcCtD
Levobupivacaine—Pain—Epirubicin—urinary bladder cancer	0.000287	0.000425	CcSEcCtD
Levobupivacaine—Constipation—Epirubicin—urinary bladder cancer	0.000287	0.000425	CcSEcCtD
Levobupivacaine—CYP1A2—Phase II conjugation—HPGDS—urinary bladder cancer	0.000287	0.0046	CbGpPWpGaD
Levobupivacaine—Urticaria—Methotrexate—urinary bladder cancer	0.000285	0.000422	CcSEcCtD
Levobupivacaine—Abdominal pain—Methotrexate—urinary bladder cancer	0.000283	0.00042	CcSEcCtD
Levobupivacaine—Body temperature increased—Methotrexate—urinary bladder cancer	0.000283	0.00042	CcSEcCtD
Levobupivacaine—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000283	0.000419	CcSEcCtD
Levobupivacaine—Insomnia—Doxorubicin—urinary bladder cancer	0.000281	0.000416	CcSEcCtD
Levobupivacaine—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000279	0.000413	CcSEcCtD
Levobupivacaine—CYP1A2—Phase II conjugation—GSTT1—urinary bladder cancer	0.000278	0.00446	CbGpPWpGaD
Levobupivacaine—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000277	0.00041	CcSEcCtD
Levobupivacaine—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000276	0.00041	CcSEcCtD
Levobupivacaine—Somnolence—Doxorubicin—urinary bladder cancer	0.000276	0.000409	CcSEcCtD
Levobupivacaine—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000274	0.000407	CcSEcCtD
Levobupivacaine—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000273	0.000405	CcSEcCtD
Levobupivacaine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000271	0.00435	CbGpPWpGaD
Levobupivacaine—CYP3A4—Biological oxidations—UGT2B7—urinary bladder cancer	0.00027	0.00433	CbGpPWpGaD
Levobupivacaine—Decreased appetite—Doxorubicin—urinary bladder cancer	0.00027	0.0004	CcSEcCtD
Levobupivacaine—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000268	0.000397	CcSEcCtD
Levobupivacaine—CYP1A2—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000266	0.00427	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000266	0.00427	CbGpPWpGaD
Levobupivacaine—Urticaria—Epirubicin—urinary bladder cancer	0.000266	0.000395	CcSEcCtD
Levobupivacaine—Constipation—Doxorubicin—urinary bladder cancer	0.000265	0.000394	CcSEcCtD
Levobupivacaine—Pain—Doxorubicin—urinary bladder cancer	0.000265	0.000394	CcSEcCtD
Levobupivacaine—Abdominal pain—Epirubicin—urinary bladder cancer	0.000265	0.000393	CcSEcCtD
Levobupivacaine—Body temperature increased—Epirubicin—urinary bladder cancer	0.000265	0.000393	CcSEcCtD
Levobupivacaine—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000264	0.000392	CcSEcCtD
Levobupivacaine—Asthenia—Methotrexate—urinary bladder cancer	0.000257	0.000381	CcSEcCtD
Levobupivacaine—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000256	0.000379	CcSEcCtD
Levobupivacaine—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000254	0.000376	CcSEcCtD
Levobupivacaine—Pruritus—Methotrexate—urinary bladder cancer	0.000253	0.000376	CcSEcCtD
Levobupivacaine—SCN4A—Developmental Biology—NCOR1—urinary bladder cancer	0.000249	0.00399	CbGpPWpGaD
Levobupivacaine—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000247	0.000367	CcSEcCtD
Levobupivacaine—Urticaria—Doxorubicin—urinary bladder cancer	0.000246	0.000366	CcSEcCtD
Levobupivacaine—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000245	0.000364	CcSEcCtD
Levobupivacaine—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000245	0.000364	CcSEcCtD
Levobupivacaine—Diarrhoea—Methotrexate—urinary bladder cancer	0.000245	0.000364	CcSEcCtD
Levobupivacaine—CYP3A4—Biological oxidations—CYP4B1—urinary bladder cancer	0.000243	0.0039	CbGpPWpGaD
Levobupivacaine—Asthenia—Epirubicin—urinary bladder cancer	0.000241	0.000357	CcSEcCtD
Levobupivacaine—SCN10A—Developmental Biology—NCOR1—urinary bladder cancer	0.00024	0.00385	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.00024	0.00385	CbGpPWpGaD
Levobupivacaine—Pruritus—Epirubicin—urinary bladder cancer	0.000237	0.000352	CcSEcCtD
Levobupivacaine—Dizziness—Methotrexate—urinary bladder cancer	0.000237	0.000352	CcSEcCtD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor—ESR1—urinary bladder cancer	0.000234	0.00375	CbGpPWpGaD
Levobupivacaine—Diarrhoea—Epirubicin—urinary bladder cancer	0.000229	0.00034	CcSEcCtD
Levobupivacaine—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000229	0.000339	CcSEcCtD
Levobupivacaine—Vomiting—Methotrexate—urinary bladder cancer	0.000228	0.000338	CcSEcCtD
Levobupivacaine—Headache—Methotrexate—urinary bladder cancer	0.000224	0.000333	CcSEcCtD
Levobupivacaine—Asthenia—Doxorubicin—urinary bladder cancer	0.000223	0.00033	CcSEcCtD
Levobupivacaine—Dizziness—Epirubicin—urinary bladder cancer	0.000222	0.000329	CcSEcCtD
Levobupivacaine—Pruritus—Doxorubicin—urinary bladder cancer	0.000219	0.000326	CcSEcCtD
Levobupivacaine—SCN4A—Axon guidance—RHOA—urinary bladder cancer	0.000217	0.00349	CbGpPWpGaD
Levobupivacaine—Vomiting—Epirubicin—urinary bladder cancer	0.000213	0.000316	CcSEcCtD
Levobupivacaine—Nausea—Methotrexate—urinary bladder cancer	0.000213	0.000316	CcSEcCtD
Levobupivacaine—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000212	0.000315	CcSEcCtD
Levobupivacaine—Headache—Epirubicin—urinary bladder cancer	0.00021	0.000312	CcSEcCtD
Levobupivacaine—CYP1A2—Biological oxidations—NAT2—urinary bladder cancer	0.00021	0.00336	CbGpPWpGaD
Levobupivacaine—SCN10A—Axon guidance—RHOA—urinary bladder cancer	0.00021	0.00336	CbGpPWpGaD
Levobupivacaine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.00021	0.00336	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000207	0.00332	CbGpPWpGaD
Levobupivacaine—Dizziness—Doxorubicin—urinary bladder cancer	0.000205	0.000304	CcSEcCtD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor—RB1—urinary bladder cancer	0.000204	0.00327	CbGpPWpGaD
Levobupivacaine—SCN4A—Axon guidance—ERBB2—urinary bladder cancer	0.000201	0.00323	CbGpPWpGaD
Levobupivacaine—Nausea—Epirubicin—urinary bladder cancer	0.000199	0.000296	CcSEcCtD
Levobupivacaine—Vomiting—Doxorubicin—urinary bladder cancer	0.000197	0.000293	CcSEcCtD
Levobupivacaine—SCN4A—Developmental Biology—CDK4—urinary bladder cancer	0.000196	0.00315	CbGpPWpGaD
Levobupivacaine—Headache—Doxorubicin—urinary bladder cancer	0.000194	0.000288	CcSEcCtD
Levobupivacaine—SCN10A—Axon guidance—ERBB2—urinary bladder cancer	0.000194	0.00311	CbGpPWpGaD
Levobupivacaine—CYP1A2—Phase II conjugation—GSTP1—urinary bladder cancer	0.000193	0.00309	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—CDK4—urinary bladder cancer	0.000189	0.00304	CbGpPWpGaD
Levobupivacaine—Nausea—Doxorubicin—urinary bladder cancer	0.000184	0.000273	CcSEcCtD
Levobupivacaine—SCN4A—Developmental Biology—PPARG—urinary bladder cancer	0.000178	0.00286	CbGpPWpGaD
Levobupivacaine—CYP1A2—Phase II conjugation—GSTM1—urinary bladder cancer	0.000177	0.00284	CbGpPWpGaD
Levobupivacaine—SCN4A—Axon guidance—MMP9—urinary bladder cancer	0.000173	0.00277	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—PPARG—urinary bladder cancer	0.000172	0.00276	CbGpPWpGaD
Levobupivacaine—SCN4A—Developmental Biology—CREBBP—urinary bladder cancer	0.000171	0.00275	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—urinary bladder cancer	0.000168	0.00269	CbGpPWpGaD
Levobupivacaine—CYP1A2—Biological oxidations—HPGDS—urinary bladder cancer	0.000168	0.00269	CbGpPWpGaD
Levobupivacaine—SCN10A—Axon guidance—MMP9—urinary bladder cancer	0.000166	0.00267	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—CREBBP—urinary bladder cancer	0.000165	0.00265	CbGpPWpGaD
Levobupivacaine—CYP1A2—Biological oxidations—GSTT1—urinary bladder cancer	0.000163	0.00261	CbGpPWpGaD
Levobupivacaine—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	0.000162	0.0026	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	0.00016	0.00256	CbGpPWpGaD
Levobupivacaine—SCN4A—Axon guidance—SRC—urinary bladder cancer	0.000159	0.00255	CbGpPWpGaD
Levobupivacaine—CYP1A2—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000157	0.00252	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—urinary bladder cancer	0.000155	0.00249	CbGpPWpGaD
Levobupivacaine—SCN4A—Developmental Biology—RHOA—urinary bladder cancer	0.000155	0.00249	CbGpPWpGaD
Levobupivacaine—SCN10A—Axon guidance—SRC—urinary bladder cancer	0.000153	0.00246	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—RHOA—urinary bladder cancer	0.00015	0.0024	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—urinary bladder cancer	0.000147	0.00235	CbGpPWpGaD
Levobupivacaine—SCN4A—Developmental Biology—ERBB2—urinary bladder cancer	0.000144	0.0023	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—urinary bladder cancer	0.000139	0.00224	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor—EP300—urinary bladder cancer	0.000139	0.00224	CbGpPWpGaD
Levobupivacaine—SCN4A—Axon guidance—EGFR—urinary bladder cancer	0.000139	0.00224	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—ERBB2—urinary bladder cancer	0.000138	0.00222	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor—SRC—urinary bladder cancer	0.000136	0.00218	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—urinary bladder cancer	0.000136	0.00218	CbGpPWpGaD
Levobupivacaine—SCN10A—Axon guidance—EGFR—urinary bladder cancer	0.000134	0.00216	CbGpPWpGaD
Levobupivacaine—SCN4A—Axon guidance—KRAS—urinary bladder cancer	0.000132	0.00211	CbGpPWpGaD
Levobupivacaine—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	0.000129	0.00207	CbGpPWpGaD
Levobupivacaine—SCN10A—Axon guidance—KRAS—urinary bladder cancer	0.000127	0.00204	CbGpPWpGaD
Levobupivacaine—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	0.000125	0.00201	CbGpPWpGaD
Levobupivacaine—SCN4A—Developmental Biology—MMP9—urinary bladder cancer	0.000123	0.00197	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor—MYC—urinary bladder cancer	0.000122	0.00195	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000121	0.00194	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—urinary bladder cancer	0.000119	0.00191	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—urinary bladder cancer	0.000119	0.00191	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—MMP9—urinary bladder cancer	0.000119	0.0019	CbGpPWpGaD
Levobupivacaine—SCN4A—Developmental Biology—EP300—urinary bladder cancer	0.000117	0.00187	CbGpPWpGaD
Levobupivacaine—SCN4A—Developmental Biology—SRC—urinary bladder cancer	0.000114	0.00182	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—urinary bladder cancer	0.000113	0.00182	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—urinary bladder cancer	0.000113	0.00182	CbGpPWpGaD
Levobupivacaine—CYP1A2—Biological oxidations—GSTP1—urinary bladder cancer	0.000113	0.00181	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—EP300—urinary bladder cancer	0.000113	0.00181	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—urinary bladder cancer	0.000112	0.0018	CbGpPWpGaD
Levobupivacaine—SCN4A—Axon guidance—HRAS—urinary bladder cancer	0.000112	0.0018	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000111	0.00178	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—SRC—urinary bladder cancer	0.000109	0.00176	CbGpPWpGaD
Levobupivacaine—SCN10A—Axon guidance—HRAS—urinary bladder cancer	0.000108	0.00173	CbGpPWpGaD
Levobupivacaine—CYP1A2—Biological oxidations—GSTM1—urinary bladder cancer	0.000104	0.00166	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000102	0.00164	CbGpPWpGaD
Levobupivacaine—SCN4A—Developmental Biology—EGFR—urinary bladder cancer	9.95e-05	0.0016	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—EGFR—urinary bladder cancer	9.59e-05	0.00154	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—urinary bladder cancer	9.55e-05	0.00153	CbGpPWpGaD
Levobupivacaine—SCN4A—Developmental Biology—TNF—urinary bladder cancer	9.48e-05	0.00152	CbGpPWpGaD
Levobupivacaine—SCN4A—Developmental Biology—KRAS—urinary bladder cancer	9.4e-05	0.00151	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—TNF—urinary bladder cancer	9.14e-05	0.00147	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—KRAS—urinary bladder cancer	9.06e-05	0.00145	CbGpPWpGaD
Levobupivacaine—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	8.7e-05	0.00139	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	8.58e-05	0.00138	CbGpPWpGaD
Levobupivacaine—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	7.99e-05	0.00128	CbGpPWpGaD
Levobupivacaine—SCN4A—Developmental Biology—HRAS—urinary bladder cancer	7.99e-05	0.00128	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	7.88e-05	0.00126	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—HRAS—urinary bladder cancer	7.7e-05	0.00124	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—GSTZ1—urinary bladder cancer	6.9e-05	0.00111	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—GSTO2—urinary bladder cancer	6.54e-05	0.00105	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—NAT1—urinary bladder cancer	6.54e-05	0.00105	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	6.44e-05	0.00103	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—UGT2B7—urinary bladder cancer	5.99e-05	0.00096	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—CYP4B1—urinary bladder cancer	5.39e-05	0.000864	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	5.33e-05	0.000855	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—SLC19A1—urinary bladder cancer	5.09e-05	0.000816	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	5.05e-05	0.00081	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—NAT1—urinary bladder cancer	5.05e-05	0.00081	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—PRSS3—urinary bladder cancer	4.96e-05	0.000796	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	4.62e-05	0.000741	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	4.16e-05	0.000667	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	3.98e-05	0.000638	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—TYMP—urinary bladder cancer	3.97e-05	0.000636	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	3.93e-05	0.00063	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	3.83e-05	0.000614	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	3.81e-05	0.000611	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—NAT2—urinary bladder cancer	3.59e-05	0.000575	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—RRM2—urinary bladder cancer	3.1e-05	0.000496	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—TYMP—urinary bladder cancer	3.06e-05	0.000491	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—ENO2—urinary bladder cancer	2.87e-05	0.00046	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	2.87e-05	0.00046	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.85e-05	0.000457	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	2.78e-05	0.000446	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—NAT2—urinary bladder cancer	2.77e-05	0.000444	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.74e-05	0.000439	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—RRM2—urinary bladder cancer	2.39e-05	0.000383	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—NQO1—urinary bladder cancer	2.31e-05	0.000371	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.24e-05	0.00036	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—ENO2—urinary bladder cancer	2.21e-05	0.000355	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	2.21e-05	0.000355	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	2.15e-05	0.000344	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.96e-05	0.000314	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	1.93e-05	0.000309	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.86e-05	0.000299	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—TYMS—urinary bladder cancer	1.79e-05	0.000287	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—NQO1—urinary bladder cancer	1.78e-05	0.000286	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	1.77e-05	0.000284	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	1.77e-05	0.000284	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—GPX1—urinary bladder cancer	1.7e-05	0.000272	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	1.67e-05	0.000267	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	1.57e-05	0.000251	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	1.49e-05	0.000239	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—TYMS—urinary bladder cancer	1.38e-05	0.000222	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	1.37e-05	0.000219	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	1.37e-05	0.000219	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—GPX1—urinary bladder cancer	1.31e-05	0.00021	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	1.29e-05	0.000206	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—PPARG—urinary bladder cancer	1.27e-05	0.000204	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	1.22e-05	0.000196	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	1.21e-05	0.000194	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	9.98e-06	0.00016	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—PPARG—urinary bladder cancer	9.8e-06	0.000157	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	9.41e-06	0.000151	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—PTEN—urinary bladder cancer	8.71e-06	0.00014	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—EP300—urinary bladder cancer	8.3e-06	0.000133	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	7.71e-06	0.000124	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—PTEN—urinary bladder cancer	6.72e-06	0.000108	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—EP300—urinary bladder cancer	6.41e-06	0.000103	CbGpPWpGaD
